Literature DB >> 25085280

Methods of diagnosis of patients with Pompe disease: Data from the Pompe Registry.

Priya S Kishnani1, Hernán M Amartino2, Christopher Lindberg3, Timothy M Miller4, Amanda Wilson4, Joan Keutzer4.   

Abstract

Pompe disease is a rare, autosomal recessive disorder characterized by deficiency of lysosomal acid alpha-glucosidase and accumulation of lysosomal glycogen in many tissues. The variable clinical manifestations, broad phenotypic spectrum, and overlap of signs and symptoms with other neuromuscular diseases make diagnosis challenging. In the past, the diagnosis of Pompe disease was based on enzyme activity assay in skin fibroblasts or muscle tissue. In 2004, methods for measuring acid alpha-glucosidase activity in blood were published. To compare how diagnostic methods changed over time and whether they differed by geographic region and clinical phenotype, we examined diagnostic methods used for 1059 patients enrolled in the Pompe Registry in three onset categories (Group A: onset of signs/symptoms ≤ 12 months of age with cardiomyopathy; Group B: onset ≤ 12 months without cardiomyopathy and onset >1 year to ≤ 12 years; Group C: onset >12 years). Enzyme activity-based assays were used more frequently than other diagnostic methods. Measuring acid alpha-glucosidase activity in blood (leukocytes, lymphocytes, or dried-blood spot) increased over time; use of muscle biopsy decreased. The increased use of blood-based assays for diagnosis may result in a more timely diagnosis in patients across the clinical spectrum of Pompe disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Dried blood spots; GAA enzyme assays; Lysosomal storage disorder; Pompe disease; Registry

Mesh:

Year:  2014        PMID: 25085280     DOI: 10.1016/j.ymgme.2014.07.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

Review 2.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

3.  PRKAG2 mutations presenting in infancy.

Authors:  Rachel D Torok; Stephanie L Austin; Chanika Phornphutkul; Kathleen M Rotondo; Deeksha Bali; Gregory H Tatum; Stephanie B Wechsler; Anne F Buckley; Priya S Kishnani
Journal:  J Inherit Metab Dis       Date:  2017-08-11       Impact factor: 4.982

4.  Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation.

Authors:  Xiao Liu; Zhaoxia Wang; Weina Jin; He Lv; Wei Zhang; Chengli Que; Yu Huang; Yun Yuan
Journal:  BMC Med Genet       Date:  2014-12-20       Impact factor: 2.103

5.  The Classification, Natural History and Treatment of the Limb Girdle Muscular Dystrophies.

Authors:  Alexander Peter Murphy; Volker Straub
Journal:  J Neuromuscul Dis       Date:  2015-07-22

6.  Respiratory manifestations in late-onset Pompe disease: a case series conducted in Brazil.

Authors:  Bruna de Souza Sixel; Luanda Dias da Silva; Nicolette Celani Cavalcanti; Glória Maria Cardoso de Andrade Penque; Sandra Lisboa; Dafne Dain Gandelman Horovitz; Juan Clinton Llerena
Journal:  J Bras Pneumol       Date:  2017 Jan-Feb       Impact factor: 2.624

Review 7.  Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU).

Authors:  Pol F Boudes
Journal:  Drugs R D       Date:  2017-06

8.  GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry.

Authors:  Arnold J J Reuser; Ans T van der Ploeg; Yin-Hsiu Chien; Juan Llerena; Mary-Alice Abbott; Paula R Clemens; Virginia E Kimonis; Nancy Leslie; Sonia S Maruti; Bernd-Jan Sanson; Roberto Araujo; Magali Periquet; Antonio Toscano; Priya S Kishnani
Journal:  Hum Mutat       Date:  2019-08-07       Impact factor: 4.878

9.  Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation.

Authors:  Mandat Maharaj; David L Skidmore; Sidney E Croul; David J Brake; Hanns Lochmuller
Journal:  Mol Genet Metab Rep       Date:  2022-07-18

10.  The Outcome of Infantile Onset Pompe Disease in South of Iran.

Authors:  Hossein Moravej; Zohre Karamizadeh; Maryam Paran
Journal:  Iran J Pediatr       Date:  2016-01-30       Impact factor: 0.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.